Aditxt Inc. (ADTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aditxt Inc. (ADTX) has a cash flow conversion efficiency ratio of 0.265x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.34 Million) by net assets ($-8.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aditxt Inc. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Aditxt Inc. 's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Aditxt Inc. carry for a breakdown of total debt and financial obligations.
Aditxt Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aditxt Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Athelney Trust plc
LSE:ATY
|
0.006x |
|
Oneiro Energy PLC
LSE:ONE
|
N/A |
|
Nuformix plc
LSE:NFX
|
-0.296x |
|
AETHER CATALYST SOLUT.
F:2QZ
|
N/A |
|
S&W Seed Company
NASDAQ:SANW
|
-0.159x |
|
Indus Gas Limited
LSE:INDI
|
0.006x |
|
Thruvision Group PLC
LSE:THRU
|
-0.076x |
|
Phoenix Global Mining Ltd
LSE:PXC
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Aditxt Inc. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Aditxt Inc. from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Aditxt Inc. .
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.29 Million | $-16.76 Million | -2.023x | -74.73% |
| 2023-12-31 | $16.05 Million | $-18.58 Million | -1.158x | +73.08% |
| 2022-12-31 | $5.21 Million | $-22.39 Million | -4.301x | -96.55% |
| 2021-12-31 | $10.18 Million | $-22.28 Million | -2.188x | -233.69% |
| 2020-12-31 | $11.01 Million | $-7.22 Million | -0.656x | -502.79% |
| 2019-12-31 | $-2.85 Million | $-464.35K | 0.163x | -35.23% |
| 2018-12-31 | $-1.54 Million | $-386.26K | 0.251x | -96.10% |
| 2017-12-31 | $-59.90K | $-386.26K | 6.448x | -- |
About Aditxt Inc.
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a n… Read more